Stoke Therapeutics (NASDAQ: STOK) CFO sells 4,578 shares to cover RSU tax

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. Chief Financial Officer Thomas Leggett reported issuer-mandated sales of 4,578 shares of common stock on March 17–18, 2026 to satisfy tax withholding obligations tied to vesting of restricted stock units. The shares were sold in multiple open-market transactions at weighted-average prices generally in the low‑$30s, with individual trades ranging from $30.59 to $33.855 per share. Following these transactions, he directly holds 10,172 shares of Stoke Therapeutics common stock, indicating the activity was a tax-related disposition rather than a complete exit from his equity position.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leggett Thomas

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		S(1)		1,274	D	$32.7394(2)	13,476	D
Common Stock	03/17/2026		S(1)		922	D	$33.3754(3)	12,554	D
Common Stock	03/18/2026		S(1)		2,173	D	$31.2838(4)	10,381	D
Common Stock	03/18/2026		S(1)		172	D	$31.7888(5)	10,209	D
Common Stock	03/18/2026		S(1)		37	D	$32.85	10,172	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive.

5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive.

	/s/ Jonathan Allan, Attorney-in-Fact	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Stoke Therapeutics (STOK) CFO Thomas Leggett report in this Form 4?

He reported issuer-mandated share sales for taxes. Leggett disclosed sales of 4,578 Stoke Therapeutics common shares to cover tax withholding from restricted stock unit vesting, rather than a discretionary reduction of his equity stake.

How many Stoke Therapeutics (STOK) shares did the CFO dispose of and at what prices?

He disposed of 4,578 shares in total. The shares were sold across multiple open-market trades at weighted-average prices around the low-$30s, with individual transaction ranges from $30.59 up to $33.855 per share.

Why were Thomas Leggett’s Stoke Therapeutics (STOK) shares sold according to the filing?

The sales were to satisfy tax withholding obligations. The filing states the issuer mandated these transactions to cover tax liabilities triggered by the vesting and settlement of Leggett’s restricted stock units, making them tax-related rather than purely elective sales.

How many Stoke Therapeutics (STOK) shares does the CFO hold after these transactions?

He directly holds 10,172 shares after the sales. The Form 4 shows that following the tax-related dispositions on March 17–18, 2026, Leggett’s remaining direct ownership position in Stoke Therapeutics common stock totals 10,172 shares.

Were Thomas Leggett’s Stoke Therapeutics (STOK) share sales routine tax withholding events?

The filing characterizes them as tax-withholding sales. A footnote explains the issuer mandated these transactions specifically to meet tax withholding liabilities from restricted stock unit vesting, indicating a routine compensation-related event.

On what dates did the Stoke Therapeutics (STOK) CFO’s reported share sales occur?

The reported sales occurred on March 17 and 18, 2026. Multiple open-market transactions over these two days covered the 4,578 shares sold to satisfy tax withholding obligations linked to restricted stock unit vesting.